Thirty years of pioneering research led by Professor Berit Johansen at the Norwegian University of Science and Technology aimed at identifying the pro-inflammatory roles and signalling cascades of the cPLA2- enzyme have given rise to Coegin Pharma, a Nordic biotech company ready to take its lead candidate AVX001 to the clinic. Here, BioStock takes a closer look at this journey from concept to clinical development, and how Professor Johansen was able to bring her vision to fruition.

Read the full interview with Professor Berit Johansen at biostock.se:

https://www.biostock.se/en/coegin-pharmas-journey-from-concept-to-the-clinic/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

https://news.cision.com/coegin-pharma-ab/r/biostock--coegin-pharma-s-journey-from-concept-to-the-clinic,c3364073

(c) 2021 Cision. All rights reserved., source Press Releases - English